Who
Jason A. Leverone
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, OnKure Therapeutics; Chief Financial Officer, Viridian Therapeutics.
In numbers
- Trades disclosed
- 43
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $19K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Feb 2017
- Last trade
- 21 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 23 Sep 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $898302 at $2.97 | filing |
| 21 Sep 2026filed 23 Sep 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $897302 at $2.97 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,781 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,781 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,781 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,781 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,322 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,322 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —130,611 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,611 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,322 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,322 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —130,611 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,611 | filing |
| 22 Jun 2026filed 24 Jun 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,332303 at $4.40 | filing |
| 22 Jun 2026filed 24 Jun 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,333303 at $4.40 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.